KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Taxes (2016 - 2022)

Travere Therapeutics (TVTX) has disclosed Change in Taxes for 7 consecutive years, with -$22000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Change in Taxes rose 76.34% year-over-year to -$22000.0, compared with a TTM value of $154000.0 through Dec 2022, up 100.9%, and an annual FY2025 reading of -$849000.0, down 2170.73% over the prior year.
  • Change in Taxes was -$22000.0 for Q4 2022 at Travere Therapeutics, down from $264000.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $18.8 million in Q1 2020 and bottomed at -$16.8 million in Q2 2021.
  • Average Change in Taxes over 4 years is -$128153.8, with a median of -$74000.0 recorded in 2020.
  • The sharpest move saw Change in Taxes surged 6280.26% in 2020, then plummeted 22566.22% in 2021.
  • Year by year, Change in Taxes stood at -$555000.0 in 2019, then soared by 735.32% to $3.5 million in 2020, then tumbled by 102.64% to -$93000.0 in 2021, then surged by 76.34% to -$22000.0 in 2022.
  • Business Quant data shows Change in Taxes for TVTX at -$22000.0 in Q4 2022, $264000.0 in Q3 2022, and -$93000.0 in Q4 2021.